Acelrx pharmaceuticals announces publication of clinical data showing reduced hospital length of stay and reduced opioid utilization with use of sublingual sufentanil in total joint replacement surgery

Hayward, calif., dec. 15, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of real-world data in patients undergoing total hip or total knee replacement showing decreased hospital length of stay and decreased opioid utilization following administration of sublingual sufentanil to manage acute pain compared to standard iv opioids.
ACRX Ratings Summary
ACRX Quant Ranking